Клопигрант А is an antiplatelet medication used to help reduce the risk of serious cardiovascular events in individuals with certain established conditions. It is typically utilized as part of a long-term treatment plan following a recent heart attack (myocardial infarction), a recent stroke, or in patients diagnosed with peripheral arterial disease. The primary therapeutic goal is to assist in maintaining the free flow of blood and decrease the likelihood of future serious episodes.

The medication's role is to support the circulatory system, which is crucial for high-risk patients. Use of antiplatelet medication is a key element in the long-term management strategy to prevent recurrent thrombotic events in individuals with cardiovascular disease. By supporting circulation, Клопигрант А is a component of a comprehensive approach to managing these chronic conditions.

Quick Facts: Part of a Strategy for Managing Risk of Cardiovascular Events Клопигрант А is medically indicated to help decrease the risk of major episodes such as stroke and heart attack in high-risk patients.

Regulatory References

1. See the NIH MedlinePlus guidance on the therapeutic role of P2Y12 inhibitors here

Клопигрант А (clopidogrel) is an antiplatelet medicine used in adults. Official regulatory documents define eligibility for use based strictly on a patient’s bleeding status, known allergies, and genetic profile.

Contraindications (Must Not Use)

• Active Pathological Bleeding: The medicine is contraindicated if you have uncontrolled internal bleeding, such as from a peptic ulcer or a recent intracranial hemorrhage (bleeding in the brain).
• Hypersensitivity: You must not use this medicine if you have a known allergy (hypersensitivity) to clopidogrel or any other component of the product.
• Severe Hepatic Impairment: The EMA label also contraindicates use in patients with severe liver impairment.

Conditional or Restricted Use

• Genetic Factors: Patients identified as CYP2C19 poor metabolizers have a genetic variation that reduces the drug’s effectiveness. Alternative treatments or strategies must be considered for this group.
• Pregnancy: Use during pregnancy is only advised if clearly needed, as safety data are limited.
• Pediatric Use: The safety and effectiveness of clopidogrel have not been established for pediatric patients.
• Other Impairments: Caution is advised for patients with renal impairment or moderate hepatic disease due to limited clinical experience in these populations.

Interactions with other medicines and products

Regulatory documentation outlines specific interaction patterns for Клопигрант А, a fixed-dose combination of Clopidogrel and Acetylsalicylic Acid (ASA).

Pharmacodynamic and Metabolic Interactions

Co-administration with Oral Anticoagulants is formally not recommended due to a documented additive pharmacodynamic effect that increases the intensity of bleeding. Caution is also warranted with other agents that affect hemostasis, including Heparin, Glycoprotein IIb/IIIa Inhibitors, and SSRIs or SNRIs, which carry an increased risk of bleeding. The medicine is formally contraindicated with NSAIDs in patients with a history of hypersensitivity to these agents.

Population and Timing Constraints

The regulatory label notes that individuals with the CYP2C19 poor metabolizer phenotype experience a genetic-metabolic interaction resulting in reduced active metabolite levels. Due to the documented bleeding risk, the medicine should be discontinued 7 days prior to elective surgery if temporary cessation of antiplatelet therapy is required. Low doses of ASA also require caution in patients with Gout as they may increase urate concentrations.

Dual, Irreversible Platelet Pathway Blockade

Клопигрант А establishes an antithrombotic state by simultaneously blocking two independent, critical steps in the platelet activation cascade. The combination of Acetylsalicylic Acid (ASA) and Clopidogrel represents Dual Antiplatelet Therapy (DAPT), strategically targeting pathways mediated by distinct chemical messengers.

Permanent Suppression of TXA2 Synthesis

The ASA component acts as an irreversible inhibitor of the Cyclooxygenase-1 (COX-1) enzyme within the platelet, permanently preventing the synthesis of Thromboxane A2 (TXA2). TXA2 is a signaling molecule that normally initiates platelet-to-platelet communication. This action reduces the platelet's initial ability to activate.

Irreversible P2Y12 Receptor Antagonism

The active form of Clopidogrel acts as an irreversible antagonist of the P2Y12 receptor on the platelet surface. This blockade prevents the final stage of platelet stabilization and cross-linking that is triggered by Adenosine Diphosphate (ADP). The permanent inhibition by both agents means the platelet modification persists for the entire lifespan of the affected platelet, resulting in a reduced capacity for platelet aggregation within the circulation.

Dosage and Administration

Клопигрант А is an oral, fixed-dose combination product containing clopidogrel and acetylsalicylic acid (aspirin) and is typically prescribed for patients already on separate therapy with both medications for the secondary prevention of atherothrombotic events. It is intended for continuation of dual antiplatelet therapy (DAPT) following initial treatment, such as after Acute Coronary Syndrome (ACS) or percutaneous coronary intervention (PCI) with stent placement.

General Use Guidelines

Important Safety Information

• Do not stop taking this medication suddenly without consulting your physician, as this can increase your risk of a heart attack or stroke.
• Inform your healthcare provider and dentist that you are taking Клопигрант А before any scheduled surgery or dental procedures, as it prolongs bleeding time. The need to temporarily discontinue the medication, usually 7 days before an elective procedure, must be reviewed by your prescribing doctor.
• Report any unusual or prolonged bleeding (e.g., in stool or urine, or a nosebleed that is difficult to stop) to your doctor immediately. This combination therapy carries an inherently increased risk of bleeding complications.

Research Evidence / Overview of Studies for Клопигрант А

Evidence for Secondary Prevention Following a Heart Event (Post-ACS/PCI)

Research involving the components of Клопигрант А (the combination of Clopidogrel and Acetylsalicylic Acid, or DAPT) includes numerous large-scale Randomized Controlled Trials (RCTs) and subsequent scientific meta-analyses. Researchers used these studies to explore how the two-component therapy was studied regarding the potential for future events in adults who have recently experienced a heart attack (ACS) or who have had a stent placed (PCI). The key outcomes monitored were Major Adverse Cardiovascular Events (MACE) and the rate of major bleeding events.

Findings describe patterns observed during the study periods. Research highlights changes measured during the study period where the combination therapy, when compared to taking aspirin alone, was associated with a lower documented rate of subsequent ischemic events (MACE) during the initial treatment phase. Research indicates a pattern where the combination therapy involves two outcomes tracked simultaneously: the documented change in ischemic risk and an observed change in bleeding risk.

Evidence for Short-Term Use Following a Recent Stroke or TIA

Research exploring the combination therapy in patients who have experienced a minor ischemic stroke or a high-risk Transient Ischemic Attack (TIA) primarily involves large, short-term RCTs. Researchers examined outcomes related to recurrent ischemic stroke and monitored the frequency of major bleeding events. Findings describe patterns where prompt initiation of the combination therapy was associated with a lower rate of recurrent ischemic stroke compared to aspirin monotherapy, with the most noticeable patterns documented within the first few weeks.

Research in Specific Patient Groups and Remaining Uncertainty

Evidence for the DAPT combination has been primarily evaluated in adult patients. Studies have explored specific subgroups, such as older adults and individuals with specific comorbidities like Peripheral Arterial Disease (PAD). The results apply only to the populations studied, and the major outcome trials generally excluded groups such as children or pregnant populations, meaning data for those groups remain insufficient.

Several areas remain uncertain within the broader evidence landscape. The optimal duration of therapy is still under study for many high-risk patient types. Additionally, comparative evidence is lacking from major outcome trials specifically testing the fixed-dose combination pill against taking the two medicines separately.

Key Studies & References

1. Clopidogrel versus acetylsalicylic acid for the secondary prevention of vascular diseases - Final report (IQWiG assessment of CAPRIE)
2. Dual antiplatelet therapy in coronary artery disease: A case-based approach (Includes references to CLARITY, CURE, CHARISMA trials)

Common questions about Клопигрант А (FAQ)

Q: What are the most common side effects of Clopigrant A?

According to official product information, the most frequently observed effects include general hemorrhage or bleeding, which is classified as very common (affecting more than 1 in 10 patients). Common effects (affecting up to 1 in 10 patients) include issues like abdominal pain, indigestion (dyspepsia), bruising, and gastrointestinal bleeding. These effects are generally consistent with the medicine's antiplatelet action as noted in official sources.

Q: Are there any specific foods or drinks I should avoid while on this therapy?

Regulatory information indicates that the consumption of alcohol should be avoided or limited during therapy. This caution is issued because alcohol may increase the risk of bleeding, particularly bleeding in the stomach or intestines, which is already a known risk associated with the acetylsalicylic acid component of Клопигрант А.

Q: Can I take an antacid like Tums while on Clopigrant A?

Authoritative sources suggest that common antacids may be used to help minimize certain stomach-related side effects from the acetylsalicylic acid component. Simple antacids like calcium carbonate are generally not noted in primary regulatory warnings as causing a major negative interaction with the antiplatelet effect, unlike other strong interacting medications. As with any over-the-counter medication, consulting a healthcare professional is generally recommended.

Q: Is there a generic version of Clopigrant A available?

Yes, regulatory agencies worldwide have authorized the use and production of generic versions. The active ingredients in Клопигрант А are clopidogrel and acetylsalicylic acid (ASA), and the fixed-dose combination product containing these two components is available under several different authorized generic or brand names.

Official Storage and Handling

The regulatory label mandates that Клопигрант А tablets must be stored at a controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The product must be protected from environmental factors that could compromise stability.

Regulated Disposal Procedures

Official disposal instructions for unused or expired tablets require the use of a drug take-back program when available. If a take-back program is not readily accessible, the medication should be mixed with an undesirable substance (such as used coffee grounds or dirt), placed in a sealed container, and discarded in the household trash. The tablets must not be flushed down a toilet or drain.